Jessica Jensen
Chief Tech/Sci/R&D Officer bei POINT Biopharma, Inc. (United States)
Profil
Jessica Jensen is currently the Executive Vice President-Clinical Development at POINT Biopharma, Inc. in the United States.
Prior to this, she was the Senior Vice President-Clinical Development at Progenics Pharmaceuticals, Inc. from 2018 to 2020.
She will also be the Executive Vice President-Clinical Development at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Jensen has a graduate degree from George Washington University and an undergraduate degree from St. Joseph's University.
Aktive Positionen von Jessica Jensen
| Unternehmen | Position | Beginn |
|---|---|---|
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Chief Tech/Sci/R&D Officer | 01.08.2020 |
Ehemalige bekannte Positionen von Jessica Jensen
| Unternehmen | Position | Ende |
|---|---|---|
| POIT BIOP | Chief Tech/Sci/R&D Officer | 27.12.2023 |
| PROGENICS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.08.2020 |
Ausbildung von Jessica Jensen
| George Washington University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| POIT BIOP | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Commercial Services |
